Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

Table 6 Clinical outcome in the present study and the AA pivotal trial

Survival outcome	Present study (Chemo-naïve)	COU-AA-302 study	Present study (Post-chemo)	COU-AA-301 study
Median OS, months	18.1	34.7	15.5	15.8
Median PFS, months	6.7^a	16.5^b	6.4^a	8.5^c
Median PFS, months	6.7^a	16.5^b	6.4^a	5.6^d
PSA response, %	62.1	62	50.0	29
Pain control, %	57.9^e	–	68.8^e	44^f

Abbreviations: OS overall survival, PFS progression-free survival, PSA response ≥50 % decline of PSA from baseline, PSA prostate-specific antigen
^aProstate Cancer Clinical Trials Working Group (PCWG-2) definition
^bRadiographic PFS
^cBiochemical PFS
^dRadiographic PFS
^eWithdrawal or reduction of level II or III analgesics according to WHO analgesics ladder
^fReduction of ≥30 % in the brief pain inventory-short form (BPI-SF) worst pain intensity score over the last 24 h observed at two consecutive evaluations 4 weeks apart without any increase in analgesic usage score; only patients experiencing a pain score ≥4 at baseline were included

ISSN: 1471-2490